Role of Endoscopy in Inflammatory Bowel Disease
Publication Date: May 1, 2015
Summary
We recommend colonoscopy with ileoscopy for the initial evaluation of IBD and for differentiating IBD subtypes. (⊕⊕⊕⊕)
312101
We recommend mucosal biopsy specimens from multiple sites during the initial endoscopic evaluation of IBD. (⊕⊕⊕⊕)
312101
We recommend flexible sigmoidoscopy in patients with IBD when colonoscopy is contraindicated and to evaluate for other inflammatory etiologies before escalating therapies in patients with refractory disease. (⊕⊕⊕o)
312101
We recommend that EGD be performed in pediatric patients with suspected IBD at the time of ileocolonoscopy. (⊕⊕⊕o)
312101
We recommend CE to evaluate the small intestine in patients with suspected CD who have no obstructive symptoms and negative ileocolonoscopy results. (⊕⊕⊕o)
312101
We recommend that a patency capsule, small-bowel follow-through, CT enterography, or magnetic resonance enterography be performed before CE in patients with known small-bowel CD involvement. (⊕⊕⊕o)
312101
We recommend CE in patients with known CD and unexplained symptoms only when abnormalities detected with CE will alter management. (⊕⊕⊕o)
312101
We suggest enteroscopy in patients with IBD who have abnormalities within reach of the enteroscope seen on other imaging studies to facilitate endoscopic and histologic evaluation and the potential for therapeutic interventions. (⊕⊕⊕o)
312101
We suggest EUS for characterizing and managing fistulous perianal CD in conjunction with other imaging modalities. (⊕⊕oo)
312101
We recommend the Montreal Classification System be used to standardize reporting of disease extent and IBD phenotypes for both UC and CD. (⊕⊕⊕o)
312101
We recommend endoscopic and histologic assessment of the pouch and afferent limb in symptomatic patients. (⊕⊕⊕⊕)
312101
We suggest endoscopic evaluation of the neoterminal ileum 6 to 12 months after surgery in order to risk-stratify patients whose medical management may be affected by endoscopic recurrence. (⊕⊕⊕o)
312101
We recommend that all patients with UC or CD colitis undergo a screening colonoscopy 8 years after disease onset to (1) re-evaluate extent of disease and (2) initiate surveillance for colorectal neoplasia. (⊕⊕⊕o)
312101
We recommend surveillance colonoscopy be performed every 1 to 3 years beginning after 8 years of disease in patients with UC with macroscopic or histologic evidence of inflammation proximal to and including the sigmoid colon and for patients with Crohn’s colitis with greater than one-third of colon involvement. (⊕⊕⊕o)
312101
We recommend chromoendoscopy with targeted biopsies as the preferred surveillance technique to maximize dysplasia detection. (⊕⊕⊕o)
312101
We suggest that chromoendoscopy-targeted biopsies are sufficient for dysplasia surveillance in patients with IBD and that consideration should be given to taking two biopsies from each colon segment for histologic staging to assess extent and severity of inflammation. (⊕⊕oo)
312101
We suggest that random biopsies with targeted biopsies of any suspicious appearing lesions remain a reasonable alternative for dysplasia surveillance if the yield of chromoendoscopy is reduced by significant underlying inflammation, significant pseudopolyposis, or poor preparation or if chromoendoscopy is not available. (⊕⊕oo)
312101
We recommend that patients with IBD whose polypoid dysplastic lesions have been removed completely receive endoscopic surveillance at 1 to 6 months and at 12 months, with yearly surveillance thereafter. (⊕⊕⊕o)
312101
We suggest that patients with IBD whose non-polypoid dysplastic lesions have been removed completely receive endoscopic surveillance at 1 to 6 months and at 12 months, with yearly surveillance thereafter. (⊕⊕oo)
312101
We recommend proctocolectomy in patients with IBD if a detected lesion is not endoscopically resectable, if there is evidence of dysplasia at the base of the lesion, or if endoscopically invisible HGD or multifocal LGD is found in the colon during a high-quality chromoendoscopy examination. (⊕⊕⊕o)
312101
We recommend IBD-associated benign strictures <4 cm in length manifesting obstructive symptoms be managed with endoscopic balloon dilation when feasible. (⊕⊕oo)
312101
Recommendation Grading
Disclaimer
Overview
Title
Role of Endoscopy in Inflammatory Bowel Disease
Authoring Organization
American Society for Gastrointestinal Endoscopy
Publication Month/Year
May 1, 2015
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Document Objectives
The purpose of this document is to update a previous ASGE Standards of Practice Committee Guideline providing a practical strategy for the use of endoscopy in the evaluation and management of patients with IBD.
Inclusion Criteria
Female, Male, Adolescent, Adult, Older adult
Health Care Settings
Ambulatory, Emergency care, Hospital, Outpatient
Intended Users
Medical assistant, nurse, nurse practitioner, physician, physician assistant
Scope
Assessment and screening, Diagnosis, Prevention
Diseases/Conditions (MeSH)
D003093 - Colitis, Ulcerative, D003424 - Crohn Disease, D043183 - Irritable Bowel Syndrome
Keywords
ulcerative colitis, Crohn's disease, gastrointestinal endoscopy, endoscopic procedures
Source Citation
Shergill, A. K., Lightdale, J. R., Bruining, D. H., Acosta, R. D., Chandrasekhara, V., Chathadi, K. V., … DeWitt, J. M. (2015). The role of endoscopy in inflammatory bowel disease. Gastrointestinal Endoscopy, 81(5), 1101–1121.e13. doi:10.1016/j.gie.2014.10.030
Methodology
Number of Source Documents
258
Literature Search Start Date
January 1, 1980
Literature Search End Date
March 1, 2014